Research output per year
Research output per year
Search results
-
2014
A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes
Demotte, N., Bigirimana, R., Wieërs, G., Stroobant, V., Squifflet, J. L., Carrasco, J., Thielemans, K., Baurain, J. F., Van Der Smissen, P., Courtoy, P. J. & Van Der Bruggen, P., 1 Apr 2014, In: Clinical Cancer Research. 20, 7, p. 1823-1833 11 p.Research output: Contribution to journal › Article › peer-review
-
2012
Improving the clinical efficacy of cancer vaccines by targeting immune suppression in human tumors
Demotte, N., Antonopoulos, A., Baurain, J. F., Wieërs, G., Van Baren, N. & Van Der Bruggen, P., 18 Dec 2012, Galectins and Disease Implications for Targeted Therapeutics. American Chemical Society, p. 267-288 22 p. (ACS Symposium Series; vol. 1115).Research output: Contribution in Book/Catalog/Report/Conference proceeding › Conference contribution
-
2011
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines
Wiëers, G., Demotte, N., Godelaine, D. & van der Bruggen, P., Sept 2011, In: Cancers. 3, 3, p. 2904-2954 51 p.Research output: Contribution to journal › Review article › peer-review
Open Access -
Tumor-infiltrating lymphocytes: Apparently good for melanoma patients. but why?
Cipponi, A., Wieërs, G., Van Baren, N. & Coulie, P. G., Aug 2011, In: Cancer Immunology, Immunotherapy. 60, 8, p. 1153-1160 8 p.Research output: Contribution to journal › Review article › peer-review
-
2010
A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice
Demotte, N., Wieërs, G., Van Der Smissen, P., Moser, M., Schmidt, C., Thielemans, K., Squifflet, J. L., Weynand, B., Carrasco, J., Lurquin, C., Courtoy, P. J. & Van Der Bruggen, P., 1 Oct 2010, In: Cancer Research. 70, 19, p. 7476-7488 13 p.Research output: Contribution to journal › Article › peer-review